This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Poteligeo (mogamulizumab)
General Description:
Poteligeo (mogamulizumab) is a humanized monoclonal antibody that targets CC chemokine receptor 4 (CCR4), a protein expressed on certain malignant T-cells. It is prescribed for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
By binding to CCR4, Poteligeo facilitates antibody-dependent cellular cytotoxicity (ADCC), helping the immune system recognize and destroy cancerous T-cells. This mechanism provides an important therapeutic option for patients with advanced cutaneous T-cell lymphomas.
Disease Indications:
Lymphoma (Mycosis Fungoides – MF, Sézary Syndrome – SS)
Manufacturer:
Kyorin Pharmaceuticals Co.
Usage:
Intravenous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Therapeutic Goods Administration (TGA)
Package:
• Single-dose vial × 20 mg/5 mL (4 mg/mL)
Shipping:
Cold Chain Shipping
Certain biologic medicines like Poteligeo are sensitive to heat, light, and handling. To preserve their stability and efficacy, Poteligeo is shipped under strict cold chain conditions using specialized medical couriers equipped with temperature-controlled packaging and vehicles.
While cold chain delivery can be more expensive than regular shipping, it ensures the product remains uncompromised and maintains full therapeutic effectiveness.
How to Access Poteligeo (mogamulizumab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Poteligeo (mogamulizumab) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare professionals in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
